s6y

AgomAb Therapeutics NV

Ticker
AGMB
CIK
2020932
Industry
Biological Products, (No Diagnostic Substances)

Ownership 23

  1. 4 Statement of changes in beneficial ownership of securities
  2. 4 Statement of changes in beneficial ownership of securities
  3. 4 Statement of changes in beneficial ownership of securities
  4. 4 Statement of changes in beneficial ownership of securities
  5. 4 Statement of changes in beneficial ownership of securities
  6. 4 Statement of changes in beneficial ownership of securities
  7. 4 Statement of changes in beneficial ownership of securities
  8. 4 Statement of changes in beneficial ownership of securities
  9. 4 Statement of changes in beneficial ownership of securities
  10. 4 Statement of changes in beneficial ownership of securities

All 23 ownership filings

Prospectus 5

  1. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  2. 424B4 Prospectus filed pursuant to Rule 424(b)(4)
  3. DRS/A Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
  4. DRS/A Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
  5. DRS Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy

Other 24

  1. SCHEDULE 13G/A
  2. 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
  3. 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
  4. 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
  5. 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
  6. 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
  7. 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
  8. 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
  9. 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
  10. SCHEDULE 13G

All 24 other filings